PIK3CA and acute promyelocytic leukemia: All-trans retinoic acid (ATRA) is an agent used in APL treatment because of its potential to promote the differentiation of promyelocytic leukemic cells by regulating the PI3K/Akt/mTOR pathway (Lal et al., 2005).